PE20180450A1 - Composicion de peptidos multiples - Google Patents
Composicion de peptidos multiplesInfo
- Publication number
- PE20180450A1 PE20180450A1 PE2017002531A PE2017002531A PE20180450A1 PE 20180450 A1 PE20180450 A1 PE 20180450A1 PE 2017002531 A PE2017002531 A PE 2017002531A PE 2017002531 A PE2017002531 A PE 2017002531A PE 20180450 A1 PE20180450 A1 PE 20180450A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- peptides
- combination
- composition
- multiple peptides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
Abstract
Referido a una combinacion de peptidos que comprende secuencias de aminoacidos de: SEC ID NUM. 1, SEC ID NUM. 2, SEC ID NUM. 3, SEC ID NUM. 4, SEC ID NUM. 5, SEC ID NUM. 6. La combinacion de peptidos puede estar presente en una composicion farmaceuticamente aceptable. Tambien se refiere a un metodo de diagnostico utilizando la combinacion especifica de peptidos, o determinacion de eficacia del tratamiento. La combinacion de peptidos puede ser utilizada en la terapia o prevencion de la Diabetes de Tipo 1 (T1D).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1510056.3A GB201510056D0 (en) | 2015-06-10 | 2015-06-10 | Multi-peptide composition |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180450A1 true PE20180450A1 (es) | 2018-03-05 |
Family
ID=53785229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2017002531A PE20180450A1 (es) | 2015-06-10 | 2016-06-10 | Composicion de peptidos multiples |
Country Status (27)
Country | Link |
---|---|
US (1) | US11400131B2 (es) |
EP (1) | EP3307298B1 (es) |
JP (1) | JP6969790B2 (es) |
KR (1) | KR20180023948A (es) |
CN (1) | CN107896494B (es) |
AR (1) | AR104947A1 (es) |
AU (1) | AU2016275295B2 (es) |
BR (1) | BR112017026537A2 (es) |
CA (1) | CA2984957A1 (es) |
CL (1) | CL2017003143A1 (es) |
CO (1) | CO2017012986A2 (es) |
EA (1) | EA201890007A1 (es) |
EC (1) | ECSP18001655A (es) |
ES (1) | ES2778630T3 (es) |
GB (1) | GB201510056D0 (es) |
HK (1) | HK1253094A1 (es) |
IL (1) | IL256199A (es) |
MA (1) | MA41668A1 (es) |
MX (1) | MX2017015658A (es) |
PE (1) | PE20180450A1 (es) |
PH (1) | PH12017501918A1 (es) |
PL (1) | PL3307298T3 (es) |
TN (1) | TN2017000517A1 (es) |
TW (1) | TW201712027A (es) |
UY (1) | UY36722A (es) |
WO (1) | WO2016198887A1 (es) |
ZA (1) | ZA201707873B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201913408D0 (en) * | 2019-09-17 | 2019-10-30 | King S College London | Proinsulin peptides for type 1 diabetes |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1986011B1 (en) * | 1999-04-21 | 2015-02-11 | Eisai Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
AU2002249895A1 (en) * | 2001-01-05 | 2002-07-16 | Joslin Diabetes Center, Inc. | Autoantigen composition |
GB0402129D0 (en) * | 2004-01-30 | 2004-03-03 | King S College London | Therapeutic and diagnostic peptides |
PL1709070T3 (pl) * | 2004-01-30 | 2014-01-31 | King S College London | Peptydy do leczenia chorób autoimmunologicznych |
WO2005076965A2 (en) * | 2004-02-04 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
ES2533566T3 (es) * | 2006-12-29 | 2015-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos |
CA2827894A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
EP2819689A1 (en) * | 2012-03-01 | 2015-01-07 | Yeda Research and Development Co. Ltd. | Regeneration of islet beta cells by hsp60 derived peptides |
-
2015
- 2015-06-10 GB GBGB1510056.3A patent/GB201510056D0/en not_active Ceased
-
2016
- 2016-06-08 TW TW105118185A patent/TW201712027A/zh unknown
- 2016-06-09 AR ARP160101718A patent/AR104947A1/es unknown
- 2016-06-10 WO PCT/GB2016/051726 patent/WO2016198887A1/en active Application Filing
- 2016-06-10 MA MA41668A patent/MA41668A1/fr unknown
- 2016-06-10 PL PL16729347T patent/PL3307298T3/pl unknown
- 2016-06-10 TN TNP/2017/000517A patent/TN2017000517A1/en unknown
- 2016-06-10 AU AU2016275295A patent/AU2016275295B2/en active Active
- 2016-06-10 EA EA201890007A patent/EA201890007A1/ru unknown
- 2016-06-10 MX MX2017015658A patent/MX2017015658A/es unknown
- 2016-06-10 EP EP16729347.1A patent/EP3307298B1/en active Active
- 2016-06-10 PE PE2017002531A patent/PE20180450A1/es unknown
- 2016-06-10 BR BR112017026537-0A patent/BR112017026537A2/pt not_active Application Discontinuation
- 2016-06-10 US US15/580,791 patent/US11400131B2/en active Active
- 2016-06-10 ES ES16729347T patent/ES2778630T3/es active Active
- 2016-06-10 CN CN201680033887.1A patent/CN107896494B/zh active Active
- 2016-06-10 CA CA2984957A patent/CA2984957A1/en active Pending
- 2016-06-10 UY UY0001036722A patent/UY36722A/es not_active Application Discontinuation
- 2016-06-10 KR KR1020187000588A patent/KR20180023948A/ko unknown
- 2016-06-10 JP JP2017564393A patent/JP6969790B2/ja active Active
-
2017
- 2017-10-20 PH PH12017501918A patent/PH12017501918A1/en unknown
- 2017-11-20 ZA ZA2017/07873A patent/ZA201707873B/en unknown
- 2017-12-07 IL IL256199A patent/IL256199A/en unknown
- 2017-12-07 CL CL2017003143A patent/CL2017003143A1/es unknown
- 2017-12-18 CO CONC2017/0012986A patent/CO2017012986A2/es unknown
-
2018
- 2018-01-10 EC ECIEPI20181655A patent/ECSP18001655A/es unknown
- 2018-09-28 HK HK18112481.1A patent/HK1253094A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US11400131B2 (en) | 2022-08-02 |
BR112017026537A2 (pt) | 2019-11-12 |
GB201510056D0 (en) | 2015-07-22 |
WO2016198887A1 (en) | 2016-12-15 |
CO2017012986A2 (es) | 2018-03-09 |
EP3307298A1 (en) | 2018-04-18 |
AU2016275295B2 (en) | 2021-12-09 |
HK1253094A1 (zh) | 2019-06-06 |
TN2017000517A1 (en) | 2019-04-12 |
MA41668A1 (fr) | 2018-03-30 |
CN107896494A (zh) | 2018-04-10 |
US20180221434A1 (en) | 2018-08-09 |
ECSP18001655A (es) | 2018-10-31 |
JP2018524301A (ja) | 2018-08-30 |
AR104947A1 (es) | 2017-08-23 |
CA2984957A1 (en) | 2016-12-15 |
PH12017501918A1 (en) | 2018-03-19 |
EP3307298B1 (en) | 2020-01-15 |
MX2017015658A (es) | 2018-08-15 |
TW201712027A (zh) | 2017-04-01 |
UY36722A (es) | 2017-01-31 |
ES2778630T3 (es) | 2020-08-11 |
CN107896494B (zh) | 2021-09-03 |
CL2017003143A1 (es) | 2018-05-18 |
EA201890007A1 (ru) | 2018-05-31 |
IL256199A (en) | 2018-02-28 |
AU2016275295A1 (en) | 2017-12-07 |
PL3307298T3 (pl) | 2020-06-29 |
JP6969790B2 (ja) | 2021-11-24 |
ZA201707873B (en) | 2019-05-29 |
KR20180023948A (ko) | 2018-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
MY167232A (en) | Polypeptides binding to human complement c5 | |
JP2017532343A5 (es) | ||
NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
MX2017000094A (es) | PRODUCTOS INMUNOGENICOS BASADOS EN SECUENCIAS DE AMINOACIDOS DE MUTEINA AMILOIDE ß (Aß) Y USOS DE LOS MISMOS. | |
EP4008786A3 (en) | The mirna-212/132 family as a therapeutic target | |
WO2015112902A3 (en) | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | |
RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
MY193807A (en) | T-cell receptor and uses thereof | |
MX2016008989A (es) | Fragmentos mutantes de ospa y metodos y usos relacionados con estos. | |
UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
EA201590678A1 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии | |
NZ700467A (en) | Treatments suitable for malassezia infections | |
EA201991531A1 (ru) | Способы лечения композициями линаклотида с отсроченным высвобождением | |
CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
PE20180450A1 (es) | Composicion de peptidos multiples | |
NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis |